Tonghua Dongbao announced that it had recently received the notification of acceptance of the filing of englitazone API issued by the State Food and drug administration.

Engglitazin is a highly selective SGLT2 inhibitor. It has a unique insulin independent hypoglycemic mechanism, that is, it reduces renal glucose threshold by reducing renal glucose reabsorption and promotes the direct excretion of glucose from urine. It is mainly used to improve blood glucose control in patients with type 2 diabetes. Domestic generic tablets have been listed in the domestic market since January 2020, and the net amount of domestic generic tablets has been listed in the domestic market since January 2020.